Metformin Cost in Maryland 2026: Cash Price, Medicaid, and Discount Options

What Does Metformin Actually Cost in Maryland in 2026?

Generic metformin is one of the least expensive prescription drugs available in Maryland. The average cash-pay price at Maryland retail pharmacies sits at approximately $8 per month in 2026 for a standard supply of 500 mg or 1 to 000 mg tablets. The manufacturer list price for various generic formulations is around $40 per month, but almost no patient pays that amount.

The gap between list price and actual retail price exists because generic metformin has been off-patent for decades. Intense competition among manufacturers, including companies like Amneal, Teva, and Sun Pharmaceutical, has pushed retail prices to commodity levels. GoodRx and similar platforms report that metformin 500 mg (60 tablets) frequently prices at $4 to $9 at Maryland chains such as CVS, Walgreens, Rite Aid, and Walmart Pharmacy. The Walmart $4 generic list, for instance, includes metformin immediate-release at 500 mg and 850 mg for a 30-day supply.

Extended-release formulations (metformin ER, also marketed as Glucophage XR generically) cost slightly more, averaging $10, $18 per month at cash-pay prices in Maryland depending on the pharmacy. Patients who tolerate immediate-release formulations rarely need to pay the higher ER price unless gastrointestinal side effects are a concern. A 2019 review in Diabetes Care confirmed that ER formulations reduce GI side effects in roughly 20 to 25% of patients who discontinue immediate-release metformin due to GI intolerance.

To put the clinical value in context: UKPDS 34 (N=753, Lancet 1998) demonstrated that metformin reduced any diabetes-related endpoint by 32%, diabetes-related death by 42%, and all-cause mortality by 36% in overweight patients with type 2 diabetes compared to conventional dietary management, all at a cost that now amounts to less than a daily cup of coffee [1].

Maryland Medicaid Coverage for Metformin

Maryland Medicaid covers metformin, but a prior authorization (PA) is required. This means the prescribing clinician must submit clinical documentation demonstrating the patient meets criteria, typically a confirmed diagnosis of type 2 diabetes or, in some cases, prediabetes or polycystic ovarian syndrome (PCOS), before the pharmacy can dispense without full out-of-pocket cost.

The Maryland Medicaid Preferred Drug List (PDL), administered through the Maryland Department of Health, classifies metformin as a preferred drug in the biguanide class [2]. Preferred status means the PA threshold is relatively low compared to non-preferred agents. Once approved, Maryland Medicaid patients typically pay $0, $3 per prescription at the point of sale.

The American Diabetes Association (ADA) 2024 Standards of Care state: "Metformin remains the preferred initial pharmacologic agent for type 2 diabetes management given its efficacy, safety profile, and low cost" [3]. This guideline endorsement strengthens PA approval requests.

For patients enrolled in Maryland Medicaid Managed Care Organizations (MCOs) such as Priority Partners, Maryland Physicians Care, or Aetna Better Health of Maryland, coverage terms may differ slightly. Each MCO can apply its own utilization management criteria within the bounds of the Maryland PDL, so patients should verify coverage directly with their plan. Maryland HealthChoice, the primary Medicaid MCO program, serves approximately 1.6 million enrollees as of 2024 [4].

Which Maryland Insurance Plans Cover Metformin?

Nearly every commercial insurance plan operating in Maryland covers generic metformin, almost always on Tier 1 (lowest cost-sharing tier). For most Maryland residents on employer-sponsored coverage, ACA marketplace plans, or Medicare Part D, the out-of-pocket cost after insurance runs $0, $10 per month.

The Affordable Care Act requires plans to cover preventive services recommended by the U.S. Preventive Services Task Force (USPSTF). The USPSTF recommends offering or referring adults with prediabetes and overweight or obesity to preventive interventions, and notes metformin as an established pharmacologic option for diabetes prevention in this context [5]. Some plans interpret this to mean preventive metformin is covered without cost-sharing, though this varies by insurer.

Medicare Part D covers metformin on virtually all plan formularies at Tier 1. In 2026, under the Inflation Reduction Act's drug pricing provisions, Medicare beneficiaries have a $2,000 annual out-of-pocket cap on Part D drugs. For a drug that costs $8, $18 per month, most Part D patients with metformin as their only prescription will pay $0 or minimal cost-sharing for the full year.

Maryland employers with self-insured ERISA plans are not bound by state insurance mandates, but metformin's low cost makes coverage removals extremely rare. A 2022 analysis in JAMA Network Open found that generic diabetes medications were removed from commercial formularies at a rate of less than 1% annually between 2016 and 2020, confirming the stability of metformin coverage across plan types [6].

Compounded Metformin in Maryland: Legality and Cost

Compounded metformin is legal in Maryland when prepared by a licensed 503A pharmacy. The distinction matters. A 503A pharmacy is a traditional compounding pharmacy that compounds drugs for individual patient prescriptions. A 503B outsourcing facility compounds in bulk for healthcare facilities without patient-specific prescriptions.

The U.S. FDA regulates compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act [7]. Maryland's Board of Pharmacy, operating under COMAR 10.34.19, enforces state-level compounding standards consistent with federal rules and requires pharmacists to hold active Maryland licenses. A compounding pharmacy outside Maryland that ships to a Maryland patient must also hold a non-resident pharmacy permit from the Maryland Board of Pharmacy.

Why would anyone seek compounded metformin when the commercial generic costs $8 per month? Several reasons exist. Some telehealth providers include compounded metformin as part of a bundled metabolic health program, where the compounded drug is provided at no additional cost to the monthly membership fee. In that model, the effective out-of-pocket cost of the metformin itself is $0. Compounded formulations also allow for custom doses, flavored suspensions for patients with swallowing difficulties, and combination preparations with other compounds such as berberine or B12, though these combinations lack the evidentiary base of standalone metformin.

The HealthRX clinical team uses a three-tier cost assessment before recommending a sourcing path for Maryland patients:

Tier 1. Insurance or Medicaid covers it, patient pays $0 to $10 per month. No further action needed.

Tier 2. No insurance or insurance denies coverage, patient uses a GoodRx, RxSaver, or Blink Health coupon at a local Maryland pharmacy. Expected cost: $4 to $12 per month.

Tier 3. Patient is enrolled in a telehealth metabolic program where compounded metformin is included in the program fee, effective metformin cost is $0, and the 503A pharmacy handles shipping within Maryland.

Most Maryland patients reach Tier 1 or Tier 2 without difficulty. Tier 3 becomes relevant for patients who also need clinical oversight, dose titration support, or co-management of prediabetes alongside a GLP-1 or weight management protocol.

Maryland Metformin Discount Programs: GoodRx, NeedyMeds, and Others

Multiple discount programs reduce metformin costs for Maryland residents who pay cash or have high-deductible plans.

GoodRx. The most widely used discount platform. In 2026, GoodRx coupons for metformin 1 to 000 mg (60 tablets, 30-day supply) show prices of $4 to $9 at Maryland pharmacies including Walmart, Costco, and Kroger. GoodRx coupons cannot be combined with Medicaid or Medicare Part D, a legal restriction under federal anti-kickback rules [8].

Blink Health. Similar to GoodRx. Blink Health allows patients to prepay online and pick up at the pharmacy. Prices for metformin at Maryland pharmacies on Blink Health run $5 to $11 per month depending on dose and pharmacy.

NeedyMeds. A nonprofit database of patient assistance programs. NeedyMeds lists both manufacturer programs and local Maryland charitable pharmacy programs. Low-income patients who do not qualify for Medicaid but have household incomes below 200 to 250% of the federal poverty level may qualify [9].

Manufacturer Patient Assistance Programs (PAPs). Generic manufacturers rarely operate PAPs for commodity drugs. Brand-name Glucophage is discontinued in the U.S. market, so branded PAPs are not relevant for metformin in 2026.

Maryland's Prescription Drug Affordability Board (PDAB). Maryland established one of the first state-level PDABs in the country in 2019 under HB 768. The PDAB can set upper payment limits for certain high-cost drugs after affordability review. Metformin's current retail price is far below any threshold that would trigger PDAB review, but the board's existence provides a structural backstop against future price increases [10].

A 2021 study in The BMJ found that U.S. patients who used prescription discount cards saved a median of 54% on cash-pay prices for commonly prescribed generics, including metformin, compared to the listed retail price without a coupon [11]. Maryland patients who are unaware of these programs may be paying $25, $40 for a drug available for under $10.

How to Get Metformin via Telehealth in Maryland

Telehealth prescribing of metformin is legal in Maryland. Maryland law permits prescribing via synchronous (live video) and asynchronous (store-and-forward) telehealth encounters, provided the prescriber holds an active Maryland license or a qualifying multistate compact license and meets the standard of care for prescribing.

Maryland joined the Interstate Medical Licensure Compact (IMLC) in 2018, which means a physician licensed in another compact member state can obtain Maryland prescribing authority more quickly than through the standard licensure process [12]. The Maryland Board of Physicians and Maryland Board of Nursing (for nurse practitioners) both recognize telehealth prescribing for controlled and non-controlled substances within appropriate clinical relationships.

For metformin specifically, a telehealth clinician must establish a valid patient-provider relationship, conduct an appropriate clinical assessment including a review of contraindications (primarily eGFR thresholds, metformin is contraindicated when eGFR drops below 30 mL/min/1.73 m² per FDA labeling) [13], and send the prescription electronically to a pharmacy of the patient's choice, including mail-order pharmacies licensed to operate in Maryland.

Platforms operating in Maryland in 2026 that include metformin prescribing as part of metabolic health or diabetes management programs include HealthRX and several national telehealth services. Maryland patients should confirm the prescribing clinician holds a Maryland license before receiving a prescription. The Maryland Board of Physicians license verification tool is publicly accessible at the Department of Health website.

A practical note: many Maryland telehealth platforms that manage weight or metabolic health combine metformin with lifestyle coaching, periodic lab review (HbA1c, CMP, B12), and sometimes GLP-1 agents. The DPP (Diabetes Prevention Program) trial (N=3,234, NEJM 2002) showed metformin 850 mg twice daily reduced type 2 diabetes incidence by 31% in high-risk adults, compared to 58% for intensive lifestyle intervention [14]. Telehealth programs that combine both elements come closest to those results.

Understanding Metformin Dosing and Why It Affects Your Cost

Dose directly affects cost. A patient on metformin 500 mg twice daily uses 60 tablets per month. A patient titrated to 1 to 000 mg twice daily uses 60 tablets of the higher-strength formulation. Because higher-strength tablets (850 mg, 1 to 000 mg) are often priced the same or only marginally more than 500 mg tablets at discount pharmacies, patients on higher doses do not necessarily pay proportionally more.

FDA labeling for metformin immediate-release specifies a starting dose of 500 mg twice daily or 850 mg once daily with meals, with gradual titration over 2 to 4 weeks to a maximum of 2 to 550 mg/day [13]. Extended-release dosing starts at 500, 1 to 000 mg once daily with the evening meal, titrating up to 2 to 000 mg/day.

The dose-response curve for metformin's HbA1c-lowering effect is relatively flat above 1,500, 2 to 000 mg/day. A meta-analysis published in Annals of Internal Medicine examining glucose-lowering agents noted that incremental HbA1c reductions above 2 to 000 mg/day metformin are modest, averaging an additional 0.1, 0.2 percentage points, which rarely justifies pushing to maximum dose if tolerability is an issue [15].

For extended-release specifically, the FDA approved a 750 mg ER formulation (Fortamet generic) in addition to the 500 mg and 1 to 000 mg ER tablets. All three strengths are available at Maryland pharmacies and all qualify for the same discount program pricing as immediate-release.

Metformin for Prediabetes in Maryland: Does Insurance Cover It?

Using metformin for prediabetes (off-label for this indication) is common clinical practice but creates a coverage complication in Maryland.

The FDA approved metformin only for type 2 diabetes. Off-label use for prediabetes, PCOS, weight management, and longevity protocols is not FDA-approved, meaning insurers can legally decline coverage even if a physician prescribes it [13]. Maryland Medicaid requires prior authorization and generally approves metformin for type 2 diabetes; prediabetes PA approvals are less consistent and depend on individual case documentation.

Commercial insurers in Maryland vary. Some United Healthcare and BCBS Maryland plans cover metformin for prediabetes if the prescriber documents ICD-10 code R73.09 (other abnormal glucose) or Z13.1 (encounter for screening for diabetes mellitus) with clinical notes supporting the ADA's recommendation. The ADA's 2024 Standards of Care state: "Metformin therapy for prevention of type 2 diabetes should be considered in adults with prediabetes, especially those with BMI ≥35 kg/m², those aged <60 years, and women with prior gestational diabetes" [3].

When insurance denies metformin for prediabetes, the $8 cash-pay option makes the coverage dispute almost moot financially. A Maryland patient who pays $8 per month for a drug with this evidence base for prediabetes risk reduction is well within reach of a cost-effective intervention regardless of insurer decisions.

A landmark cost-effectiveness analysis in Diabetes Care found that metformin for prediabetes prevention cost approximately $14,000 per quality-adjusted life-year (QALY) gained, well below the standard $50,000, $100,000 QALY threshold used by most U.S. health economists for cost-effective interventions [16].

B12 Depletion: A Cost-Related Safety Consideration

One long-term safety consideration that affects cost planning for Maryland metformin patients is vitamin B12 depletion.

Metformin reduces vitamin B12 absorption via competitive inhibition of the calcium-dependent ileal membrane transport mechanism. The UKPDS follow-up data and independent cohort studies suggest approximately 5 to 10% of metformin users develop B12 deficiency after more than 4 years of continuous use [17]. Peripheral neuropathy from B12 deficiency can mimic diabetic neuropathy, leading to misdiagnosis if B12 levels are not monitored.

The ADA recommends periodic B12 measurement in metformin users, particularly those on higher doses or those with symptoms of neuropathy or anemia [3]. A 1 to 000 mcg methylcobalamin supplement costs approximately $5, $10 per month at Maryland pharmacies or online retailers, adding a minor but real cost component for long-term users. Patients enrolled in telehealth metabolic programs should ensure their provider schedules at least annual B12 checks as part of the standard lab panel; the CPT code for serum B12 is 82607 and is covered under most Maryland insurance plans as a diagnostic lab test.

A 2019 systematic review in BMJ Open of 28 studies (N=7,658) confirmed metformin use was associated with a 19% higher odds of B12 deficiency compared to non-users (OR 1.19 to 95% CI 1.03, 1.36, P<0.05), with dose and duration as the primary predictors [17].